Accelmed Partners raises USD400m to invest in commercial stage healthtech
Accelmed Partners (Accelmed), a private equity firm focused on acquiring and investing in US commercial stage, lower middle market HealthTech companies, has closed its oversubscribed second fund, Accelmed Fund II (Fund II) at the fund’s hard cap of USD400 million, exceeding its original USD300 million target.
Fund II received significant backing from new investors globally, including pension funds, insurers, family offices, and high net worth individuals, as well as from existing Accelmed limited partners.
For more than a decade, Accelmed has leveraged its deep HealthTech industry experience, operational and financial expertise, and strong relationships across the field to help management teams at the companies it acquires control of or invests in position their businesses for future growth and success.
Consistent with Accelmed’s strategy of developing and transforming US HealthTech companies, Fund II identifies and executes on investments in medical devices, diagnostics, digital health, and technology-enabled healthcare services with a focus on control-oriented opportunities in companies with revenues typically between USD20 million and USD70 million. Fund II also provides a certain allocation of non-control growth capital to companies within Accelmed’s domain expertise with revenues greater than USD10 million over the past twelve months. The Fund is designed to build upon Accelmed’s strong track record of capitalising on innovative sector opportunities at a time when the demand for technology-enabled healthcare solutions has never been greater.
Dr Uri Geiger, Founder and Managing Partner of Accelmed, says: “We have built our business on the belief that increasing the conversion of healthcare and technology materially improves individuals’ lives, addresses society’s unmet healthcare needs, and ultimately drives down the cost of healthcare. The strong support Fund II received from a diverse group of institutional investors and prominent family offices is a testament to their confidence in our strategy and ability to identify companies at the nexus of healthcare and innovation and partner with them to drive significant value.
“Over the past decade, we have served as a trusted value-add partner to HealthTech companies and management teams who are looking to take their businesses to the next level but lack the resources and expertise to execute on these aspirations on their own. The result has been broader access to innovative HealthTech solutions and a portfolio of high-growth businesses that have proven resilient to the Covid pandemic. We look forward to continuing to meet the needs of lower middle market HealthTech companies with the ongoing deployment of Fund II.”